Ventyx Biosciences announces $100m IPO

Ventyx Biosciences, a medical research company which focusses on therapies for inflammatory diseases and autoimmune disorders, filed for a $100m initial public offering Wednesday.

The company’s Securities and Exchange Commission’s filing did not list the number of shares or a price range the company hopes to sell when its shares are sold on the Nasdaq under the ticker "VTYX."

Also on Thursday, the Encinitas, California-based lab said it closed on a $51m Series B convertible preferred stock finding round.

Jefferies, Evercore ISI, Piper Sandler, and LifeSci Capital are acting as joint book-runners.

Read more: No time to buy: Here are 43 James Bond investments

Related topics

#IPO

Rate this article

Rate this article:

Comment

0

Rate this article

Rate this article:

Share this article

Comments

Please note before commenting

• comments should be only on the topic of this article (please contact Support center for individual queries relating to your trading account);
• comments shouldn’t contain inappropriate content (personal attack, violence, scam, etc.);
• comments shouldn’t contain links to external websites;
• comments should match the language of the article;
• your comment will be moderated.

---

Comment

There are currently no responses for this story.
Be the first to respond.

Your comment has been submitted for moderation. We confirm that your comment will be reviewed and if it complies with the comment guidelines, it will be published.

More comments